Home Venture Capital Myosotis Raises €8M in Series A Funding

Myosotis Raises €8M in Series A Funding

38
0
Myosotis

Myosotis

Myosotis (“myo”), a Berlin, Germany-based digital healthcare startup, raised €8M in Series A funding.

The round saw participation from TVM Capital with participation from Twip. Existing shareholders included nursing home operators Agaplesion and Carpe Diem, as well as the venture capital funds BonVenture, Axel Springer Plug & Play, Think Health, Mountain Partners, Round Hill Ventures and Capacura. Dr. Sascha Berger, General Partner, and Stefan Fischer, Managing Partner (Finance) of TVM, will join the myo Board of Directors.   

The company intends to use the funds to further grow the business in the DACH region as well as in the UK. This will include expanding marketing capacity and enhancing service quality for existing customers, as well as developing new modules.

Led by CEO Jasper Böckel, Myosotis offers a software-as-a-service solution for direct digital communication between employees, relatives and the ecosystem of service providers in care homes. The app enables communication with relatives through photos, videos, voice messages and video calls. This makes the impressive work in care more visible and simplifies administrative processes at the same time. The majority of communication – whether with relatives or third-party providers – can be handled by a single digital application. With it, homes can inform all relatives about new hygiene measures, for example, let a family participate in the life of the person in need of care and inform the doctor, pharmacy or external laundry service.

myo is already working with over 400 customers in DACH and the UK, including the most well-known providers, such as DRK, AWO, Johanniter and Agaplesion.

Commenting on the news, Jasper Böckel said: “This funding is an important step in our growth plan. We are delighted to have such a well-regarded investor as TVM come on board and look forward to leveraging their experience with commercial-stage life science companies. Our passionate team is dedicated to enhancing human interactions in care settings, and these proceeds will now enable us to roll out our technology to more users and develop additional solutions for healthcare providers and families.”

FinSMEs

31/01/2024

Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here